MAP0020

MAP0020 is a specific unit-dose formulation of budesonide, a synthetic, non-halogenated corticosteroid. It is delivered via inhalation aerosol and is primarily developed for the maintenance treatment of asthma and as prophylactic therapy, particularly in children. Budesonide exerts its therapeutic effects as a potent anti-inflammatory agent by binding to and activating glucocorticoid receptors. This interaction leads to the modulation of gene expression, resulting in the reduced production of inflammatory mediators and increased synthesis of anti-inflammatory proteins, thereby alleviating asthma symptoms. Nephron Pharmaceuticals Corporation manufactures a generic Budesonide Inhalation Suspension in unit-dose vials, which aligns with the description of MAP0020.

Other names

unit dose budesonideBudesonide Inhalation Suspension